Investigation of the biological indicator for vaccine efficacy against highly pathogenic avian influenza (HPAI) H5N1 virus challenge in mice and ferrets

Vaccine

Volumn 27, Issue 24, 2009, Pages 3145-3152

  Song, Min Suk ^a   Oh, Taek Kyu ^a   Pascua, Philippe Noriel Q ^a   Moon, Ho Jin ^b   Lee, Jun Han ^a   Baek, Yun Hee ^a   Woo, Kyu Jin ^c   Yoon, Yeup ^c   Sung, Moon Hee ^d   Poo, Haryoung ^e   Kim, Chul Joong ^b   Choi, Young Ki ^a  

^a Chungbuk National University College of Medicine   (South Korea)

^b Chungnam National University   (South Korea)

^c Mogam Biotechnology Research Institute   (South Korea)

^d Bioleaders Corporation   (South Korea)

^e Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Biological marker; Cross protection; HPAI H5N1; Vaccine

Indexed keywords

BIOLOGICAL MARKER; HEMAGGLUTININ; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; SIALIDASE; SODIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AVIAN INFLUENZA; CLADISTICS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MONITORING; EXPERIMENTAL INFECTION; FERRET; FOWL; GENETICS; HOST; IMMUNITY; IMMUNIZATION; INFECTION PREVENTION; INFLUENZA VIRUS A H5N1; MORTALITY; MOUSE; NONHUMAN; PLANT GROWTH; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS TITRATION; WILD TYPE;

ANIMALS; BIOLOGICAL MARKERS; FERRETS; HEMAGGLUTINATION INHIBITION TESTS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION;

EID: 67349216211     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.03.061     Document Type: Article

References (40)

1. Claas E.C., Osterhaus A.D., van B.R., De Jong J.C., Rimmelzwaan G.F., Senne D.A., et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 351 9101 (1998) 472-477
2. Suarez D.L., Perdue M.L., Cox N., Rowe T., Bender C., Huang J., et al. Comparisons of highly virulent H5N1 influenza A viruses isolated from humans and chickens from Hong Kong. J Virol 72 8 (1998) 6678-6688
3. Shortridge K.F. Poultry and the influenza H5N1 outbreak in Hong Kong, 1997: abridged chronology and virus isolation. Vaccine 17 Suppl. 1 (1999) S26-S29
4. World Health Organization. H5N1 avian influenza: timeline of major events. 2008. Available: http://www.who.int/csr/disease/avian_influenza/timeline2008_01_02.pdf.
5. Sabirovic M., Raw L., Hall S., Lock F., and Coulson N. International disease monitoring, October to December 2005. Vet Rec 158 13 (2006) 426-428
6. De B.P., Joannis T.M., Lombin L.H., Shittu I., Beato M.S., Rebonato V., et al. Field and laboratory findings of the first incursion of the Asian H5N1 highly pathogenic avian influenza virus in Africa. Avian Pathol 36 2 (2007) 115-117
7. World Health Organization, WHO. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. Available: http://www.who.int/csr/disease/avian_influenza/country/cases_table_2008_09_10/en/index.html.
8. Subbarao K., and Luke C. H5N1 viruses and vaccines. PLoS Pathog 3 3 (2007) e40
9. Chin P.S., Hoffmann E., Webby R., Webster R.G., Guan Y., Peiris M., et al. Molecular evolution of H6 influenza viruses from poultry in Southeastern China: prevalence of H6N1 influenza viruses possessing seven A/Hong Kong/156/97 (H5N1)-like genes in poultry. J Virol 76 2 (2002) 507-516
10. Webster R.G., Guan Y., Peiris M., Walker D., Krauss S., Zhou N.N., et al. Characterization of H5N1 influenza viruses that continue to circulate in geese in southeastern China. J Virol 76 1 (2002) 118-126
11. Subbarao K., Chen H., Swayne D., Mingay L., Fodor E., Brownlee G., et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305 1 (2003) 192-200
12. Salzberg S.L., Kingsford C., Cattoli G., Spiro D.J., Janies D.A., Aly M.M., et al. Genome analysis linking recent European and African influenza (H5N1) viruses. Emerg Infect Dis 13 5 (2007) 713-718
13. Smith G.J., Fan X.H., Wang J., Li K.S., Qin K., Zhang J.X., et al. Emergence and predominance of an H5N1 influenza variant in China. Proc Natl Acad Sci USA 103 45 (2006) 16936-16941
14. Yamada S., Suzuki Y., Suzuki T., Le M.Q., Nidom C.A., Sakai-Tagawa Y., et al. Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature 444 7117 (2006) 378-382
15. Govorkova E.A., Webby R.J., Humberd J., Seiler J.P., and Webster R.G. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 194 2 (2006) 159-167
16. Schickli J.H., Flandorfer A., Nakaya T., Martinez-Sobrido L., Garcia-Sastre A., and Palese P. Plasmid-only rescue of influenza A virus vaccine candidates. Philos Trans R Soc Lond B Biol Sci 356 1416 (2001) 1965-1973
17. Hoffmann E., Krauss S., Perez D., Webby R., and Webster R.G. Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 20 25-26 (2002) 3165-3170
18. Lipatov A.S., Hoffmann E., Salomon R., Yen H.L., and Webster R.G. Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. J Infect Dis 194 8 (2006) 1040-1043
19. Subbarao K., Murphy B.R., and Fauci A.S. Development of effective vaccines against pandemic influenza. Immunity 24 1 (2006) 5-9
20. Lee C.W., Suarez D.L., Tumpey T.M., Sung H.W., Kwon Y.K., Lee Y.J., et al. Characterization of highly pathogenic H5N1 avian influenza A viruses isolated from South Korea. J Virol 79 6 (2005) 3692-3702
21. Lee Y.J., Choi Y.K., Kim Y.J., Song M.S., Jeong O.M., Lee E.K., et al. Highly pathogenic avian influenza virus (H5N1) in domestic poultry and relationship with migratory birds, South Korea. Emerg Infect Dis 14 3 (2008) 487-490
22. Reed L.J., and Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 27 (1938) 493-497
23. Horimoto T., Takada A., Fujii K., Goto H., Hatta M., Watanabe S., et al. The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. Vaccine 24 17 (2006) 3669-3676
24. Murakami S., Iwasa A., Iwatsuki-Horimoto K., et al. Cross-clade protective immunity of H5N1 influenza vaccines in a mouse model. Vaccine 26 50 (2008) 6398-6404
25. Hoffmann E., Lipatov A.S., Webby R.J., Govorkova E.A., and Webster R.G. Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc Natl Acad Sci USA 102 36 (2005) 12915-12920
26. Li H., Ding J., and Chen Y.H. Recombinant protein comprising multi-neutralizing epitopes induced high titer of antibodies against influenza A virus. Immunobiology 207 5 (2003) 305-313
27. Lu X., Tumpey T.M., Morken T., Zaki S.R., Cox N.J., and Katz J.M. A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol 73 7 (1999) 5903-5911
28. Palmer D.F., Dowdle W.R., Coleman M.T., and Schild G.C. Advanced laboratory techniques for influenza diagnosis. Immunol Ser 6 (1975) 25-45
29. Govorkova E.A., Rehg J.E., Krauss S., Yen H.L., Guan Y., Peiris M., et al. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol 79 4 (2005) 2191-2198
30. Hampson A.W. Ferrets and the challenges of H5N1 vaccine formulation. J Infect Dis 194 2 (2006) 143-145
31. Mazanec M.B., Coudret C.L., and Fletcher D.R. Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J Virol 69 2 (1995) 1339-1343
32. Suguitan Jr. A.L., McAuliffe J., Mills K.L., Jin H., Duke G., Lu B., et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 3 9 (2006) e360
33. Mahmood K., Bright R.A., Mytle N., Carter D.M., Crevar C.J., Achenbach J.E., et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26 42 (2008) 5393-5399
34. Swayne D.E., Lee C.W., and Spackman E. Inactivated North American and European H5N2 avian influenza virus vaccines protect chickens from Asian H5N1 high pathogenicity avian influenza virus. Avian Pathol 35 2 (2006) 141-146
35. Isoda N., Sakoda Y., Kishida N., Soda K., Sakabe S., Sakamoto R., et al. Potency of an inactivated avian influenza vaccine prepared from a non-pathogenic H5N1 reassortant virus generated between isolates from migratory ducks in Asia. Arch Virol 153 9 (2008) 1685-1692
36. Ellis T.M., Leung C.Y., Chow M.K., Bissett L.A., Wong W., Guan Y., et al. Vaccination of chickens against H5N1 avian influenza in the face of an outbreak interrupts virus transmission. Avian Pathol 33 4 (2004) 405-412
37. Maines T.R., Lu X.H., Erb S.M., Edwards L., Guarner J., Greer P.W., et al. Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J Virol 79 18 (2005) 11788-11800
38. Yen H.L., Monto A.S., Webster R.G., and Govorkova E.A. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis 192 4 (2005) 665-672
39. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370 9587 (2007) 580-589
40. Atmar R.L., Keitel W.A., Patel S.M., Katz J.M., She D., El Sahly H., et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 43 9 (2006) 1135-1142